2Niederman MS;Mandell LA;Anzueto A.Guidelines for the management of adults with community-acquired pneumonia.Diagnosis,assessment of severity,antimicrobial therapy,and prevention,2001(07).
3Felmingham D;Grüneberg RN.The Alexander Project 1996-1997:latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections[J],2000.
4Song JH;Lee NY;Ichiyama S.Spread of drug-resistant Streptococcus pneumoniae in Asian countries:Asian network for suiveillance of resistant pathogens(ANSO-RP) study,1999(28).
5Bartlett JG;Breiman RF;Mandell LA.Community-acquired pneumonia in adults:guidelines for management[J],1998(4).
6Heffelfinger JD;Dowell SF;Jorgensen JH.Management of community-acquired pneumonia in the era of pneumococcal resistance:a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group,2000.
8Pfaller MA;Jones RN.Antimicrobial susceptibility of inducible AmpC beta-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection(MYSTIC) Programme,Europe 1997-2000[J],2002(19).
8Anzueto A. Impact of exacerbations on COPD[J].European Respiratory Review,2010,(116):113-118.
9Rothberg M,Pekow P,Lahti M. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease[J].Journal of the American Medical Association,2010,(20):2035-2042.
10Sethi S,Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease[J].New England Journal of Medicine,2008,(22):2355-2365.doi:10.1056/NEJMra0800353.
